GlassScriptPhysician profile
Glenn D Carli
NPI 1619914181
$4,029.33
in general payments reported to CMS, 2019-2025
20 companies · $672 in 2025
The $672 reported for 2025 was more than what 84% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $595 · 2020: $350 · 2021: $258 · 2022: $1,210 · 2023: $550 · 2024: $394 · 2025: $672.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,598 · Education: $17.84.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,598.28 |
| Education | $17.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $952.64 | 2019-2025 | Precision 1, Precision7, Dailies Total1 |
| Johnson & Johnson Vision Care, INC. | $755.42 | 2020-2022 | |
| Bausch & Lomb Americas INC. | $496.01 | 2023-2025 | Miebo, Infuse, Infuse Multifocal |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $336.01 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $287.17 | 2019-2023 | |
| Coopervision INC. | $279.47 | 2019-2024 | Myday Contact Lens |
| Dompe US, INC. | $155.66 | 2025 | Oxervate |
| Regeneron Healthcare Solutions, INC. | $125.00 | 2022 | |
| Apellis Pharmaceuticals, INC. | $99.48 | 2023 | Syfovre |
| Abbvie INC. | $89.38 | 2024-2025 | |
| Lkc Technologies, INC. | $81.58 | 2024 | |
| Shire North American Group INC | $74.27 | 2019 | |
| Sun Pharmaceutical Industries INC. | $54.06 | 2021-2023 | Cequa |
| Allergan, INC. | $51.65 | 2020-2022 | |
| Kala Pharmaceuticals, INC. | $49.24 | 2021-2022 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Oyster Point Pharma, INC. | $46.68 | 2022-2025 | Ryzumvi, Tyrvaya |
| Tarsus Pharmaceuticals, INC. | $41.99 | 2024-2025 | Xdemvy |
| Biotissue Holdings INC. | $20.94 | 2025 | |
| Thea Pharma INC. | $16.41 | 2023 | |
| Maculogix, INC. | $16.27 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Glenn Carli listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.